Search | IOVS | ARVO Journals

Showing 1 – 20 of 21

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Anatomy and Pathology/Oncology December 2022

Detectability of Plasma-Derived Circulating Tumor DNA Panel in Patients Undergoing Primary Treatment for Uveal Melanoma

PDF

Jasmine H. Francis; Christopher A. Barker; A. Rose Brannon; Julia Canestraro; Melissa Robbins; Christina E. Swartzwelder; Sara Levine; Crystal Law; Michael F. Berger; Alexander Shoushtari; David H. Abramson
TAGS: circulating tumor dna, intraocular melanoma, plasma
Invest. Ophthalmol. Vis. Sci.. 2022; 63(13):17. https://doi.org/10.1167/iovs.63.13.17

Includes: Supplemental Content

Physiology and Pharmacology March 2021

NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs

PDF

Elena Bastia; Carol B. Toris; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Michael V. W. Bergamini; Emanuela Masini; Silvia Sgambellone; Andrea M. Unser; Feryan Ahmed; Karen Y. Torrejon; Tomas Navratil; Francesco Impagnatiello
TAGS: animal model, dog, domestic, intraocular pressure, ocular hypertension, oryctolagus cuniculus, nitric oxide, primates, donors, cyclic gmp
Invest. Ophthalmol. Vis. Sci.. 2021; 62(3):17. https://doi.org/10.1167/iovs.62.3.17

ARVO Annual Meeting Abstract June 2020

Intraocular pressure (IOP)-lowering effects of NCX 1770, a dual acting new chemical entity with nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitory properties in rabbit and non-human primate models of ocular hypertension and glaucoma

Elena Bastia; Carol Toris; Michael V W Bergamini; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1232.

ARVO Annual Meeting Abstract June 2020

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma

Francesco Impagnatiello; Tomas Navratil; Carol Toris; Michael V W Bergamini; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2786.

ARVO Annual Meeting Abstract July 2019

TearLab Discovery Quantification of MMP-9 Levels in Patients With Significant Inflammatory Eye Disease and Concordance with InflammaDry

Benjamin Sullivan; Carolina Betancurt Garcia; Janet I Teng; Tanaeya Hovington; Michael S Berg; Daniel Cohen; Victor L Perez

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6791.

ARVO Annual Meeting Abstract July 2019

Preclinical Evaluation of NCX 4251, a Novel Steroid Therapy for Blepharitis, Targeted Directly to the Eyelid Margin to Reduce the Potential for IOP Elevations

Tomas Navratil; Jean-Michel Bukowski; Frederic Pilotaz; Amanda Graves; Akshay Nadkarni; Amber Allen; Brigitte Duquesroix; Elena Bastia; Laura Storoni; Angela Kothe; Michael V W Bergamini; Jay Pennell; Brian G Short; Thomas Walters; Robert D Fechtner; Donald L Budenz

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6755.

ARVO Annual Meeting Abstract July 2019

Concomitant dosing of the NO-donor NCX 667 (1%) and Xalatan® (latanoprost ophthalmic solution 0.005%) results in robust and sustained IOP-lowering in ocular normotensive dogs

Michael V W Bergamini; Tomas Navratil; Francesco Impagnatiello; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3193.

ARVO Annual Meeting Abstract July 2019

NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma

Francesco Impagnatiello; Elena Bastia; Carol B Toris; Shan Fan; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Michael V W Bergamini

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3770.

ARVO Annual Meeting Abstract July 2019

Nonclinical development of NCX 470, a novel nitric oxide (NO)-donating,IOP lowering prostaglandin analog for glaucoma and ocular hypertension

Elena Bastia; Nicoletta Almirante; Michael V W Bergamini; Tomas Navratil; Marlene Woodruff Modi; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3806.

ARVO Annual Meeting Abstract June 2017

Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma

Elena Bastia; Francesco Impagnatiello; Ennio Ongini; Janet B Serle; Michael V W Bergamini

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2106.

ARVO Annual Meeting Abstract September 2016

IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits

Elena Bastia; Emanuela Masini; Mariaconcetta Durante; Michael V.W. Bergamini; Ennio Ongini; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3031.

ARVO Annual Meeting Abstract September 2016

Intraocular pressure-lowering and ocular exposure of NCX 1653, a novel nitric oxide-donating travoprost in models of ocular hypertension and glaucoma

Francesco Impagnatiello; Laura Storoni; Stefania Brambilla; Emanuela Masini; Cecilia Lanzi; Carol B Toris; Michael V.W. Bergamini; Ennio Ongini; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3034.

ARVO Annual Meeting Abstract September 2016

Pharmacological inhibition of nitric oxide increases myopia susceptibility in mice

Ranjay Chakraborty; Michael A. Bergen; Erica Landis; Duk Cheon Lee; P. Michael Iuvone; Machelle T Pardue

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

Visual Neuroscience August 2016

Altered Refractive Development in Mice With Reduced Levels of Retinal Dopamine

PDF

Michael A. Bergen; Han na Park; Ranjay Chakraborty; Erica G. Landis; Curran Sidhu; Li He; P. Michael Iuvone; Machelle T. Pardue
TAGS: dopamine, mice, myopia
Invest. Ophthalmol. Vis. Sci.. 2016; 57(10):4412-4419. https://doi.org/10.1167/iovs.15-17784

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2015

Retinal-specific Dopamine Knock-out Mice are Myopic.

Michael A Bergen; Han na Park; Ranjay Chakraborty; Erica G Landis; Curran Sidhu; P Michael Iuvone; Machelle T Pardue

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2153.

ARVO Annual Meeting Abstract June 2015

Melanopsin knock-out mice have abnormal refractive development and increased susceptibility to form-deprivation myopia.

Ranjay Chakraborty; Duk Cheon Lee; Erica G Landis; Michael A Bergen; Han na Park; Curran Sidhu; Samer Hattar; P Michael Iuvone; Richard A Stone; Machelle T Pardue

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5843.

ARVO Annual Meeting Abstract June 2013

Real World Analytical Performance of the TearLab Osmolarity System with an Enhanced Temperature Sensor

Benjamin Sullivan; Stephen Zmina; Matthew Zmina; Michael Berg

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4336.

ARVO Annual Meeting Abstract June 2013

The Influence of Punctal Occlusion on Osmolarity in Dry Eye Subjects

David Eldridge; Michael Berg; Benjamin Sullivan; William Townsend

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):6048.

ARVO Annual Meeting Abstract April 2011

Longitudinal Variability Of Biomarkers for Dry Eye Disease - Implications for Clinical Trials

Benjamin D. Sullivan; Baris Sonmez; María F. de la Paz; Michael S. Berg; Michael A. Lemp

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3804.

Research Article August 2005

Short-term predictive changes in the dynamics of disparity vergence eye movements

PDF

Tara L. Alvarez; Mayur Bhavsar; John L. Semmlow; Michael T. Bergen; Claude Pedrono
TAGS: conditioning (psychology), eye movement, health disparity, velocity, recovery of function
Journal of Vision. 2005; 5(7):4. https://doi.org/10.1167/5.7.4

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Detectability of Plasma-Derived Circulating Tumor DNA Panel in Patients Undergoing Primary Treatment for Uveal Melanoma

NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs

Intraocular pressure (IOP)-lowering effects of NCX 1770, a dual acting new chemical entity with nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitory properties in rabbit and non-human primate models of ocular hypertension and glaucoma

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma

TearLab Discovery Quantification of MMP-9 Levels in Patients With Significant Inflammatory Eye Disease and Concordance with InflammaDry

Preclinical Evaluation of NCX 4251, a Novel Steroid Therapy for Blepharitis, Targeted Directly to the Eyelid Margin to Reduce the Potential for IOP Elevations

Concomitant dosing of the NO-donor NCX 667 (1%) and Xalatan® (latanoprost ophthalmic solution 0.005%) results in robust and sustained IOP-lowering in ocular normotensive dogs

NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma

Nonclinical development of NCX 470, a novel nitric oxide (NO)-donating,IOP lowering prostaglandin analog for glaucoma and ocular hypertension

Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma

IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits

Intraocular pressure-lowering and ocular exposure of NCX 1653, a novel nitric oxide-donating travoprost in models of ocular hypertension and glaucoma

Pharmacological inhibition of nitric oxide increases myopia susceptibility in mice

Altered Refractive Development in Mice With Reduced Levels of Retinal Dopamine

Retinal-specific Dopamine Knock-out Mice are Myopic.

Melanopsin knock-out mice have abnormal refractive development and increased susceptibility to form-deprivation myopia.

Real World Analytical Performance of the TearLab Osmolarity System with an Enhanced Temperature Sensor

The Influence of Punctal Occlusion on Osmolarity in Dry Eye Subjects

Longitudinal Variability Of Biomarkers for Dry Eye Disease - Implications for Clinical Trials

Short-term predictive changes in the dynamics of disparity vergence eye movements

To View More...

You must be signed into an individual account to use this feature.